Ono Pharma and Aitia Announce Collaboration to Identify Novel Drug Targets in Neurological Diseases
Deep knowledge of complex neurological disease biology revealed by Aitia’s Gemini Digital Twin Platform will be used to derisk the discovery and development of Ono’s new pipeline programs.
September 1, 2026 – Osaka, Japan and Cambridge, MA, USA
Aitia, whose causal AI-powered Gemini Digital Twin Platform uniquely uncovers complex disease biology and applies that knowledge to pharmaceutical discovery and development, and Ono Pharmaceutical Co., Ltd (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced a collaboration to bring their respective strengths together to discover novel neurological disease targets and develop effective new therapeutics.
“A critical reason we have so few effective treatments for most neurological diseases is our ongoing, fundamental lack of knowledge of their complex biological causes,” said Colin Hill, CEO and co-founder of Aitia. “We believe that working with Ono’s world-class medical and pharmaceutical development experts to build comprehensive in silico Gemini Digital Twins of neurological disease will help uncover new validated drug targets and drive rational discovery approaches that lead to effective interventions.”
“Ono has a long and proud history of developing pharmaceuticals for many significant unmet medical needs,” said Seishi Katsumata, Corporate Officer/Executive Vice President, Discovery & Research of Ono. “We are committed to applying that same expertise and passion to the treatment of devastating neurological diseases, and we believe that collaborating closely with Aitia’s researchers to deeply understand the underlying complex biology will best accelerate successful therapeutic discovery and development.”